HEL Xenograft Model Service for Leukemia

The HEL cell line serves as a specialized and highly representative in vivo platform for studying erythroleukemia, particularly for evaluating therapeutic responses in JAK2V617F-mutated myeloid malignancies. As a premier pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision HEL Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your leukemia drug discovery and development pipeline.

Overview of HEL Xenograft Model for Leukemia

The HEL xenograft model is an established in vivo translational system widely utilized in hematological oncology research for the study of erythroleukemia. By transplanting human HEL myeloid cells into highly permissive, immunodeficient rodent hosts, this model effectively reproduces the systemic dissemination, bone marrow infiltration, and distinct pathophysiological profiles characteristic of progressive human leukemia.

Biologically, the HEL model is uniquely valued for its constitutive expression of the JAK2V617F mutation, which drives aberrant cytokine signaling and uncontrolled blast proliferation. This model preserves critical molecular features, including erythroid-myeloid lineage markers and sensitivity to JAK-STAT pathway inhibitors. Consequently, the HEL model is extensively deployed in pre-clinical screening programs to assess the anti-leukemic potency of novel small-molecule inhibitors, targeted monoclonal antibodies, and combination therapeutic regimens in a physiologically relevant in vivo setting.

Fig 1. sh-2C #3 validation in HEL cells and H3K9me3 blot of JMJD2C-depleted or wt HEL cells. (Staehle AM, et al., 2023)

Cell Line Information: HEL

The HEL cell line was established from the peripheral blood of a patient with erythroleukemia. These cells grow as suspension cultures under standard in vitro laboratory parameters, maintaining a stable myeloblastic phenotype that serves as a robust proxy for myeloid malignancy research.

Our Services

Workflow of HEL Xenograft Model Construction

• Cell Culture & Quality Control: Human HEL cells are expanded in vitro using certified nutrient suspension media under optimized growth parameters. STR authentication and mycoplasma clearance verification are completed prior to inoculation to ensure absolute phenotypic identity and biological purity.
• Host Selection & Acclimatization: Standardized, healthy immunodeficient mice (e.g., NSG or NOD/SCID strains) are sourced from validated vendors. The animals undergo a dedicated acclimatization phase to stabilize baseline biological and physiological metrics.
• Precision Inoculation: A calibrated suspension of high-viability HEL cells is prepared in a sterile physiological buffer. The cellular suspension is precisely inoculated in vivo into the host cohorts via tail vein intravenous routes to facilitate systemic leukemic distribution and marrow engraftment.
• Longitudinal Growth Tracking: Following inoculation, disease progression is systematically monitored using FACS to detect human CD45+ cells or lineage-specific markers in peripheral blood. Animal weight, physical clinical indicators, and systemic disease burden are documented routinely.
• Stratification & Dosing: Once peripheral leukemic chimerism reaches a predetermined, statistically optimal range, the mice are randomized into matched experimental cohorts to ensure balanced baseline systemic dimensions before the initiation of customized therapeutic dosing regimens.

Fig 2. HEL Xenograft Model Construction Workflow

Case Study - HEL Xenograft Model Development

A pre-clinical validation study was conducted using the HEL xenograft model to evaluate the therapeutic efficacy of a novel JAK-STAT pathway inhibitor designed for erythroleukemia. Following precision intravenous inoculation of human HEL cells into immunodeficient mice, the animals exhibited steady, systemic leukemic engraftment and highly predictable disease progression across all study cohorts. Animals assigned to the active treatment group demonstrated a clear, statistically significant reduction in circulating leukemic blasts and prolonged survival times compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted myeloid therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse hematological and myeloid lineages, providing highly reproducible in vivo translational platforms for complex leukemia research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive FACS metrics and robust statistical validations.

Contact us

Accelerating your leukemia pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our HEL platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.